Last updated 4/02/2020
Since the onset of the coronavirus (COVID-19) outbreak, AdvaMed member companies have donated millions of dollars’ worth of medical products and cash to hospitals, foundations and charities around the world. Medical device companies are responding to increased demand by ramping up production wherever possible, coordinating closely with governments to ensure the delivery of supplies where they are most needed, and in some cases, creating new devices and diagnostic tests to help effectively diagnose and treat sick patients.
Below is a collection of some of the efforts undertaken recently by AdvaMed member companies based on public statements.
View a list of companies that have developed IVDs that have received Emergency Use Authorization from the U.S. Food and Drug Administration.
3M has ramped up to maximum production of N95 respirators, doubling their global output to a rate of 1.1 billion per year, or 100 million per month. This includes 35 million per month in the United States, and over just the last seven days (as of March 31) has delivered 10 million N95 respirators to healthcare facilities in states across the country.
3M plans to double their capacity to reach 2 billion globally within the next 12 months – and some of that additional capacity will begin to come online in the next 60-90 days.
In the United States, 3M expects to be producing N95 respirators at a rate of 50 million per month in June, a 40 percent increase from current levels. Read More.
Abbott has received emergency use authorization (EUA) from the FDA for its molecular test for the identification of SARS-CoV-2, the virus that causes COVID-19.
The company is deploying 150,000 laboratory tests immediately. Tests already have been sent to hospital and academic medical center labs in 18 states including Illinois, California, New York, Massachusetts and Washington. Abbott is scaling up production at its U.S. manufacturing location to reach capacity for one million tests per week by end of March. Read more.
Bayer has donated medicine and money with a total value of approximately EUR 1.5M to China. View the press release. Bayer is also supporting hospitals in Lombardy, Italy, with a donation of $1M euros. The money is being added to an aid fund that the regional authorities in Lombardy have set up to help procure urgently needed equipment for intensive care units in hospitals with the greatest needs. Besides Italy, Bayer has already sent considerable financial and material support to China to help contain the pandemic. Bayer will continue to provide affected regions and countries with rapid and unbureaucratic assistance as part of its corporate social responsibility. Read more.
BD (Becton, Dickinson and Company) and BioGX Inc, a molecular diagnostics company, have submitted Emergency Use Authorization (EUA) requests to the U.S. Food and Drug Administration (FDA) for new diagnostic tests that, if authorized, would increase the potential capacity to screen for COVID-19 by thousands of tests per day.
The tests will be run on the BD MAX™ automated Molecular Diagnostic Platform, which is already in use in nearly every state across the U.S. at hundreds of laboratories, with each unit capable of analyzing hundreds of samples per day. Samples are capable of being analyzed start to finish in two to three hours. Each BD MAX™ System can process 24 samples simultaneously. BD CEO and President Tom Polen stated, “We are working around the clock internally and with external partners to increase the coronavirus diagnostic capacity in the U.S by ramping up production of our sample collection tools and increasing access to our automated molecular platform for in vitro diagnostics.” Read more.
BD has contributed over $1M for COVID-19 response efforts, including $350,000 in cash and company product donations for relief efforts in China earlier this year. View the press release here.
Boston Scientific has donated more than $1.3M in supplies to hospitals, including protective masks, goggles, gloves and other protective items to meet the urgent needs of health care providers. In addition, Boston Scientific launched an employee match donation program supporting Project HOPE, a global health and humanitarian relief organization with people on the ground working to get supplies and support to front line health care workers. Read more.
BioMérieux has announced the forthcoming launch of three different tests to address the COVID-19 epidemic and to meet the different needs of physicians and health authorities in the fight against this emerging infectious disease. Read more.
Cardinal Health stated: “Simply, our focus is on providing a safe and secure work environment for our employees and their families, ensuring our customers have access to the medical supplies and pharmaceuticals they need to support their patients, and acting as a reliable, dependable partner for the health care community.” Read more.
Cepheid has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19. The first commercially available point-of-care test for COVID-19, the test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes. Read more.
Danaher Corporation: Five Danaher operating companies donated RMB 10 million ($1.4M) of diagnostic equipment, reagents and other products to hospitals in Wuhan, China to combat COVID-19. Included in the donation is: Beckman Coulter Diagnostics' hematology analyzers, Beckman Coulter Life Sciences' flow cytometers, Radiometer's blood gas analyzers, Cepheid's Xpert® Xpress Flu/RSV assay, and Hach's UV-Vis spectrometers.
ExThera's Seraph®100 Microbind® Affinity Blood Filter, which is CE-marked in Europe for reduction of pathogens in blood, is being used to treat COVID-19 in Germany and Italy, the firm reports, though "more clinical results are needed to confirm patient benefit in COVID-19." Read more.
GE Healthcare CEO Kieran Murphy shared that the company is accelerating manufacturing with plans to rapidly deliver around 1,000 pieces of technology, such as CTs, ultrasounds, monitors and ventilators, among several other response efforts. Read more.
Hologic created a fully automated test that detects genetic material from SARS-CoV-2, the new coronavirus strain, in under three hours. The test recently was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA). Read more.
Johnson & Johnson has earmarked $50M for COVID-19 response efforts, primarily focused on supporting frontline health workers. This includes product donations in China, Italy, South Korea, and more, with over $3.7M in personal protective equipment like goggles, protective suits and masks. J&J is also working diligently to convert manufacturing lines at several facilities around the world to produce hand sanitizer in accordance to FDA and CDC guidelines as quickly as possible that will help protect R&D, manufacturing and distribution employees, and to be donated to health and community service workers on the front lines of care. Read more here. Additionally, J&J is working with partners to develop a vaccine. Read more here and here.
The Lilly Foundation contributed $500,000 to United Way of Central Indiana’s Community Economic Relief Fund. The fund will support human services organizations and the individuals and families they serve who are affected directly or indirectly by the COVID-19 virus. The Lilly Foundation is also providing a 2:1 match for Lilly employee and retiree contributions to the fund.
Lilly and AbCellera agreed to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus. The collaboration will leverage AbCellera's rapid pandemic response platform and Lilly's global capabilities for rapid development, manufacturing and distribution of therapeutic antibodies. Read more.
Medtronic continues to make progress in increasing ventilator production worldwide. The company has increased production by more than 40 percent to date and is on track to more than double its capacity to manufacture and supply ventilators in response to the urgent needs of patients and healthcare systems across the globe confronting COVID-19. Read more.
Olympus installed endoscope systems into the Wuhan Huo Shen Shan Hospital within 10 days to treat infected patients. In addition to monetary donations to the Red Cross Society of China Huanggang, Olympus has donated 15 sets of laryngoscopes to the China Social Welfare Foundation, and 25 biological microscopes to the Chinese Center for Disease Control and Prevention, totaling approximately $500,000 in donations.
PMT Partners announced up to 1,000 Emergency Ventilators – Resuscitators are available for clinical use. “We have 1,000 combined Oxylator HD and Oxylator EMX devices available for hospitals and emergency medical services,” said Larry Kronick, President of PMT Partners. “Oxylator technology has helped thousands of patients during resuscitation and short-term ventilation in the USA, Europe, and Asia.” Read more.
QIAGEN has sent the first group of 200 QIAstat-Dx cartridges for syndromic detection of respiratory pathogens – including COVID-19 –to China; they’re now being validated at four hospitals. This comes as an evaluation was also successfully completed at the Bichat-Claude Bernard Hospital in Paris. The use of QIAstat-Dx is increasingly important for detection of the COVID-19 infections, as well as to provide differential diagnostics involving the more than 20 other respiratory pathogens included in this syndromic test.
Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Lyra® SARS-CoV-2 Assay, a real-time RT-PCR test intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19 by their healthcare provider. Read more.
ResMed CEO Mick Farrell stated March 23 that over 7,500 ResMed employees are working diligently in over 140 countries with government officials and health care workers to maximize production and delivery of essential ventilators and other respiratory support devices. The company is looking to double or triple ventilator output, and scale up ventilation mask production by tenfold. Read more here. Earlier this year, the firm reported sending over 100 ventilators from its facility near Shanghai to Wuhan, with plans to send hundreds more and thousands of masks. Read more.
Roche announced on March 13, 2020 that the U.S. FDA has issued an Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 test for qualitative detection of the virus that causes COVID-19 disease. Additionally, Roche has donated medical supplies and financial support for China's affected region. Read the company's statement.
Smith+Nephew has been working to support its employees and customers in China. They are liaising closely with the local authorities, supporting urgent cases and donating product, in particular from their Advanced Wound Care range, and cash via the Red Cross, in aggregate worth approximately $250,000. Chief Executive Officer, Roland Diggelmann, shared the following statement, “Smith+Nephew has been responding to the COVID-19 outbreak for many weeks, first in China, and now in countries across the world. Our focus is to protect the health and well-being of our employees while continuing to serve customers. The commitment of our employees has ensured we have kept our products and services flowing. We stand together ready to offer assistance during this unprecedented and challenging period.” Read more.